Muhammad Yaseen

Mr. Muhammad Yaseen

Institute of chemical sciences, University of Swat, Mingora, Pakistan
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2023 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
AAAbdelrahman Hamdi Abdelkhalek
Abdelrahman Hamdi Abdelkhalek
Muhammad YaseenMuhammad Yaseen
Muhammad Yaseen
WEWafaa Ewes
Wafaa Ewes
Mashooq Ahmad BhatMashooq Ahmad Bhat
Mashooq Ahmad Bhat
NZNoha I. Ziedan
Noha I. Ziedan
MEMostafa M. Elbadawi
Mostafa M. Elbadawi
This research study describes the development of new small molecules based on 2,4-thiazolidinedione (2,4-TZD) and their aldose reductase (AR) inhibitory activities. The synthesis of 17 new derivatives of 2,4-TZDs hybrids was feasible by incorporating two known bioactive scaffolds, benzothiazole heterocycle, and nitro phenacyl moiety. The most active hybrid (8b) was found to inhibit AR in a non-competitive manner (0.16 µM), as confirmed by kinetic studies and molecular docking simulations. Furthermore, the in vivo experiments demonstrated that compound 8b had a significant hypoglycaemic effect in mice with hyperglycaemia induced by streptozotocin. Fifty milligrams per kilogram dose of 8b produced a marked decrease in blood glucose concentration, and a lower dose of 5 mg/kg demonstrated a noticeable antihyperglycaemic effect. These outcomes suggested that compound 8b may be used as a promising therapeutic agent for the treatment of diabetic complications.

27 May 2024 in Molecules
Verified
Journal Article
Open access
PDF file
MAMd. Ahad Ali
Md. Ahad Ali
HSHumaira Sheikh
Humaira Sheikh
Muhammad YaseenMuhammad Yaseen
Muhammad Yaseen
Md Omar FaruqeMd Omar Faruqe
Md Omar Faruqe
IUIhsan Ullah
Ihsan Ullah
MMMd. Nurul Haque Mollah
Md. Nurul Haque Mollah
The outbreak of SARS-CoV-2, also known as the COVID-19 pandemic, is still a critical risk factor for both human life and the global economy. Although, several promising therapies have been introduced in the literature to inhibit SARS-CoV-2, most of them are synthetic drugs that may have some adverse effects on the human body. Therefore, the main objective of this study was to carry out an in-silico investigation into the medicinal properties of Petiveria alliacea L. (P. alliacea L.)-mediated phytocompounds for the treatment of SARS-CoV-2 infections since phytochemicals have fewer adverse effects compared to synthetic drugs. To explore potential phytocompounds from P. alliacea L. as candidate drug molecules, we selected the infection-causing main protease (Mpro) of SARS-CoV-2 as the receptor protein. The molecular docking analysis of these receptor proteins with the different phytocompounds of P. alliacea L. was performed using AutoDock Vina. Then, we selected the three top-ranked phytocompounds (myricitrin, engeletin, and astilbin) as the candidate drug molecules based on their highest binding affinity scores of −8.9, −8.7 and −8.3 (Kcal/mol), respectively. Then, a 100 ns molecular dynamics (MD) simulation study was performed for their complexes with Mpro using YASARA software, computed RMSD, RMSF, PCA, DCCM, MM/PBSA, and free energy landscape (FEL), and found their almost stable binding performance. In addition, biological activity, ADME/T, DFT, and drug-likeness analyses exhibited the suitable pharmacokinetics properties of the selected phytocompounds. Therefore, the results of this study might be a useful resource for formulating a safe treatment plan for SARS-CoV-2 infections after experimental validation in wet-lab and clinical trials.

7 December 2023 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Open access
Abdelmoujoud FarisAbdelmoujoud Faris
Abdelmoujoud Faris
IIIbrahim M. Ibrahim
Ibrahim M. Ibrahim
Radwan ِAlnajjarRadwan ِAlnajjar
Radwan ِAlnajjar
HHHanine Hadni
Hanine Hadni
Mashooq Ahmad BhatMashooq Ahmad Bhat
Mashooq Ahmad Bhat
MEMenana Elhallaoui
Menana Elhallaoui
This study presents a robust and integrated methodology that harnesses a range of computational techniques to facilitate the design and prediction of new inhibitors targeting the JAK3/STAT pathway. This methodology encompasses several strategies, including QSAR analysis, pharmacophore modeling, ADMET prediction, covalent docking, molecular dynamics (MD) simulations, and the calculation of binding free energies (MM/GBSA). An efficacious QSAR model was meticulously crafted through the employment of multiple linear regression (MLR). The initial MLR model underwent further refinement employing an artificial neural network (ANN) methodology aimed at minimizing predictive errors. Notably, both MLR and ANN exhibited commendable performance, showcasing R2 values of 0.89 and 0.95, respectively. The model's precision was assessed via leave-one-out cross-validation (CV) yielding a Q2 value of 0.65, supplemented by rigorous Y-randomization. , The pharmacophore model effectively differentiated between active and inactive drugs, identifying potential JAK3 inhibitors, and demonstrated validity with an ROC value of 0.86. The newly discovered and designed inhibitors exhibited high inhibitory potency, ranging from 6 to 8, as accurately predicted by the QSAR models. Comparative analysis with FDA-approved Tofacitinib revealed that the new compounds exhibited promising ADMET properties and strong covalent docking (CovDock) interactions. The stability of the new discovered and designed inhibitors within the JAK3 binding site was confirmed through 500 ns MD simulations, while MM/GBSA calculations supported their binding affinity. Additionally, a retrosynthetic study was conducted to facilitate the synthesis of these potential JAK3/STAT inhibitors. The overall integrated approach demonstrates the feasibility of designing novel JAK3/STAT inhibitors with robust efficacy and excellent ADMET characteristics that surpass Tofacitinib by a significant margin.Communicated by Ramaswamy H. Sarma.

4 June 2024 in Molecular Biotechnology
Verified
Journal Article
Closed access
PDF file
Md. Tarikul IslamMd. Tarikul Islam
Md. Tarikul Islam
AKAktaruzzaman
Aktaruzzaman
ASAhmed Saif
Ahmed Saif
AAAyesha Akter
Ayesha Akter
MBMashooq Ahmad Bhat
Mashooq Ahmad Bhat
MRMd Obayed Raihan
Md Obayed Raihan

29 March 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
BABasharat Ahmad
Basharat Ahmad
ASAamir Saeed
Aamir Saeed
AAAhmed Al-Amery
Ahmed Al-Amery
ICIsmail Celik
Ismail Celik
IAIraj Ahmed
Iraj Ahmed
Mashooq Ahmad BhatMashooq Ahmad Bhat
Mashooq Ahmad Bhat
Histone deacetylases (HDACs) are enzymes that remove acetyl groups from ɛ-amino of histone, and their involvement in the development and progression of cancer disorders makes them an interesting therapeutic target. This study seeks to discover new inhibitors that selectively inhibit HDAC enzymes which are linked to deadly disorders like T-cell lymphoma, childhood neuroblastoma, and colon cancer. MOE was used to dock libraries of ZINC database molecules within the catalytic active pocket of target HDACs. The top three hits were submitted to MD simulations ranked on binding affinities and well-occupied interaction mechanisms determined from molecular docking studies. Inside the catalytic active site of HDACs, the two stable inhibitors LIG1 and LIG2 affect the protein flexibility, as evidenced by RMSD, RMSF, Rg, and PCA. MD simulations of HDACs complexes revealed an alteration from extended to bent motional changes within loop regions. The structural deviation following superimposition shows flexibility via a visual inspection of movable loops at different timeframes. According to PCA, the activity of HDACs inhibitors induces structural dynamics that might potentially be utilized to define the nature of protein inhibition. The findings suggest that this study offers solid proof to investigate LIG1 and LIG2 as potential HDAC inhibitors.

29 June 2023 in Molecules
Verified
Journal Article
Open access
PDF file
SSSubhash Sharma
Subhash Sharma
VKVikas Kumar
Vikas Kumar
Muhammad YaseenMuhammad Yaseen
Muhammad Yaseen
Amr Salah AbouziedAmr Salah Abouzied
Amr Salah Abouzied
AAAbgeena Arshad
Abgeena Arshad
KDKamal Dev
Kamal Dev
Potentilla nepalensis Hook is a perennial Himalayan medicinal herb of the Rosaceae family. The present study aimed to evaluate biological activities such as the antioxidant, antibacterial, and anticancer activities of roots and shoots of P. nepalensis and its synergistic antibacterial activity with antibacterial drugs. Folin–Ciocalteau and aluminium chloride methods were used for the calculation of total phenolic (TPC) and flavonoid content (TFC). A DPPH radical scavenging assay and broth dilution method were used for the determination of the antioxidant and antibacterial activity of the root and shoot extracts of P. nepalensis. Cytotoxic activity was determined using a colorimetric MTT assay. Further, phytochemical characterization of the root and shoot extracts was performed using the Gas chromatography–mass spectrophotometry (GC-MS) method. The TPC and TFC were found to be higher in the methanolic root extract of P. nepalensis. The methanolic shoot extract of P. nepalensis showed good antioxidant activity, while then-hexane root extract of P. nepalensis showed strong cytotoxic activity against tested SK-MEL-28 cells. Subsequently, in silico molecular docking studies of the identified bioactive compounds predicted potential anticancer properties. This study can lead to the production of new herbal medicines for various diseases employing P. nepalensis, leading to the creation of new medications.